Document is current
Any future updates will be listed below
-
Authors
Hagiwara, Masayuki
Fushimi, Atsushi
Yamashita, Nami
Bhattacharya, Atrayee
Rajabi, Hasan
Long, Mark D. https://orcid.org/0000-0003-1120-8176
Yasumizu, Yota https://orcid.org/0000-0002-1725-6454
Oya, Mototsugu
Liu, Song
Kufe, Donald https://orcid.org/0000-0001-5743-8888
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA97098, CA166480, CA233084, CA232979)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 8 January 2021
Revised: 20 May 2021
Accepted: 7 June 2021
First Online: 23 June 2021
Competing interests
: DK has equity interests in Genus Oncology, Reata Pharmaceuticals and Hillstream BioPharma and is a paid consultant to Reata and CanBas. The other authors declared no competing interests.
